Premier Alternatives

J-Pharma (TKS: 520A)

Tokyo, Japan · Founded 2005 · Publicly Held

J-Pharma Co Ltd is engaged in the Drug discovery and development targeting SLC transporters. J-Pharma (TKS: 520A) is based in Tokyo, Japan and was founded in 2005. It is now publicly traded; this page covers its private-market history, where its last recorded valuation was $99.4 million (Mar 2026). It has raised $83.1 million.

Last price · $/share
—
Implied valuation
$99.4M
Total raised
$83.1M
Last round
—

J-Pharma (TKS: 520A) key facts

  • J-Pharma Co Ltd is engaged in the Drug discovery and development targeting SLC transporters.
  • J-Pharma (TKS: 520A)’s last known valuation is $99.4M (Mar 2026).
  • It has raised $83.1M; the latest was IPO ($20.8M) in Mar 2026.
  • Notable investors include Mitsubishi UFJ Capital, F-Prime Capital, Eight Roads, Japan External Trade Organization, JIC Venture Growth Investments — 30 tracked in total.
  • Status: Publicly Held.
Free account
More of J-Pharma (TKS: 520A) with a free account
  • ·The complete investor list: 30 names
  • ·Watch J-Pharma (TKS: 520A): the Monday email on marks, rounds and moves
Create free account
No card required

Membership and data by Private Market View

J-Pharma (TKS: 520A) funding rounds

No rounds on record

No funding rounds for J-Pharma (TKS: 520A) are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.

Pro members can request priority coverage with a 48-hour turnaround.

J-Pharma (TKS: 520A) valuation

J-Pharma (TKS: 520A) is now publicly traded; this page covers its private-market history, where its last recorded valuation was $99.4 million (Mar 2026). Secondary trades, fund marks and rounds below are the private-market record; the listed share price is not tracked here.

J-Pharma (TKS: 520A) investors

30 investors are on record for J-Pharma (TKS: 520A), including Mitsubishi UFJ Capital, F-Prime Capital, Eight Roads and Japan External Trade Organization. By type, the record holds 4 venture capital firms and 1 asset manager.

About J-Pharma (TKS: 520A)

J-Pharma Co Ltd is engaged in the Drug discovery and development targeting SLC transporters. It is focused on a single segment of the drug discovery business, focusing on R&D and clinical development. The company's two compounds in clinical development are Nanbran Latte (JPH203) and JPH034.

Sector
Healthcare
HQ
Tokyo, Japan
Founded
2005
Employees
16
Ownership
Publicly Held

Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.

Valuation on record
$99.4M

J-Pharma (TKS: 520A)’s last known valuation, Mar 2026. A PrivateMarketView mark is published once fund marks, secondary prints or a priced round let us confirm it.